IP Library Granted Patent US 10,709,756
Granted Patent B2
US 10,709,756 · App. 16/345,170 · Granted Jul 14, 2020

Treating sexual dysfunction

Inventor: E. Quattrocki Knight (Belmont, MA)
Assignee: Olive Therapeutics, LLC
A61K38/095A61K9/0043A61K31/137A61P15/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,709,756
App. No.
16/345,170
Granted
Jul 14, 2020
Kind
B2
Abstract

The present disclosure describes use of oxytocin, in combination with one or more other agents as described herein, for use for example in the treatment of certain conditions.

Claims (6)

1. A method comprising: administering to a woman suffering from sexual dysfunction intranasal oxytocin and sublingual buspirone, so that the subject receives combination therapy with both.

2. The method of claim 1 , wherein the sexual dysfunction is (i) delayed orgasm and/or (ii) difficulty achieving orgasm and is secondary to current and/or prior use of psychotropic medications.

3. The method of claim 1 , wherein the subject does not adequately respond to available medications or is unable to tolerate available medications because of side effects and/or contraindications.

4. The method of claim 1 , wherein the step of administering occurs approximately 30 minutes to six hours, 30 minutes to 60 minutes, or 5 minutes to 20 minutes prior to sexual activity.

5. The method of claim 1 , wherein the subject is a post-menopausal-woman.

6. The method of claim 1 , wherein the oxytocin is administered prior to, subsequent to, or concomitant with the buspirone.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE TYPOGRAPHICAL ERROR IN THE U.S. APPLICATION NUMBER 16354170 AS LISTED ON SCHEDULE A PREVIOUSLY RECORDED ON REEL 052369 FRAME 0500. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 18, 2020
From: REVIVE PHARMACEUTICALS LLC
To: OLIVE THERAPEUTICS, LLC
Reel/Frame 052694/0221 →
CORRECTIVE ASSIGNMENT TO CORRECT THE TYPOGRAPHICAL ERROR IN THE U.S. APPLICATION NUMBER 16354170 AS LISTED ON SCHEDULE A PREVIOUSLY RECORDED ON REEL 052369 FRAME 0476. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 18, 2020
From: REVIVE PHARMACEUTICALS, LLC
To: REVIVE PHARMACEUTICALS LLC
Reel/Frame 052694/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2020
From: REVIVE PHARMACEUTICALS, LLC
To: REVIVE PHARMACEUTICALS LLC
Reel/Frame 052369/0476 →
Continuity (2)
Provisional Application 62413328 · Oct 26, 2016
Related Publication 20190282653A1 · Sep 19, 2019